Cemsidomide in Combination With Elranatamab

A Phase 1B, Open-label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
60 patients (estimated)
Tags
IKZF1/3
Trial Type
Treatment
Last Update
SparkCures ID
2219
NCT Identifier
NCT07280013

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.